Lv3
220 积分 2022-07-30 加入
The MAPK signalling pathways and colorectal cancer
4个月前
已完结
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance
4个月前
已关闭
Decay of driver mutations shapes the landscape of intestinal transformation
4个月前
已完结
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance
4个月前
已完结
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
6个月前
已完结
Improved Clinical Outcomes with Low-Dose Anti–CTLA-4 (Nurulimab) Plus Anti–PD-1 (Prolgolimab) vs. Anti–PD-1 Monotherapy in Advanced Cutaneous Melanoma: Results from the Phase III OCTAVA Trial
8个月前
已完结
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
8个月前
已完结
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
8个月前
已完结
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
8个月前
已完结
Prolgolimab with Chemotherapy as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer
8个月前
已完结
皖公网安备34019202002308
